Medicine and Health

A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants

Y. Du, R. Shi, et al.

Discover the groundbreaking research on h11B11, an ACE2-blocking monoclonal antibody that demonstrates exceptional efficacy in inhibiting SARS-CoV and SARS-CoV-2. Conducted by an expert team including Yanyun Du and Rui Shi, this study unveils promising therapeutic and preventive strategies against viral replication with minimal toxicity.

00:00

Playback language: English

Index

Abstract

The study isolates and humanizes an ACE2-blocking monoclonal antibody (h11B11) showing potent inhibitory activity against SARS-CoV and SARS-CoV-2 lineages. Therapeutic and prophylactic administration in a mouse model alleviated and prevented viral replication and associated syndromes. High-dose injections in cynomolgus monkeys showed no significant toxicity. Structural analysis revealed the antibody's mechanism involves hindering and competing with the RBD for ACE2 binding. This suggests h11B11 as a potential therapeutic countermeasure.

Publisher

Nature Communications

Published On

Aug 17, 2021

Authors

Yanyun Du, Rui Shi, Ying Zhang, Xiaomin Duan, Li Li, Jing Zhang, Fengze Wang, Ruixue Zhang, Hao Shen, Yue Wang, Zheng Wu, Qianwen Peng, Ting Pan, Wanwei Sun, Weijin Huang, Yue Feng, Hui Feng, Junyu Xiao, Wenjie Tan, Youchun Wang, Chenhui Wang, Jinghua Yan

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection

L. M. Coria, J. M. Rodriguez, et al.

Medicine and Health

A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery

X. Zhang, H. Zhang, et al.

Medicine and Health

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

C. Kim, D. Ryu, et al.

Medicine and Health

A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration

H. Ma, X. Zhang, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny